论文部分内容阅读
目的:探讨依折麦布联合阿托伐他汀对冠心病患者氧化应激及血脂水平的影响及临床疗效。方法:选择2013年8月-2016年8月于我院接受治疗的冠心病患者144例,随机分为对照组和研究组,每组72例。对照组患者给予阿托伐他汀及硝酸甘油治疗,研究组患者给予阿托伐他汀和依折麦布治疗。观察并比较两组患者治疗前后血清过氧化物酶(MPO)、丙二醇(MDA)、超氧化物歧化酶(SOD)、总胆固醇(TC)、甘油三脂(TG)、低密度脂蛋白(LDL-C)及高密度脂蛋白(HDL-C)水平、心功能及临床疗效。结果:研究组患者临床总有效率(87.5%)效显著高于对照组(76.4%),差异具有统计学意义(P<0.05);治疗后,两组患者血清MDA及MPO水平均降低,而SOD水平均升高,差异具有统计学意义(P<0.05);与对照组比较,治疗后研究组患者血清MDA及MPO水平较低,而SOD水平较高,差异具有统计学意义(P<0.05)。治疗后,两组患者血清HDL-C水平均升高,而LDL-C,TC及TG水平均降低,差异具有统计学意义(P<0.05);与对照组比较,治疗后研究组患者血清HDL-C水平较高,而LDL-C,TC及TG水平较低,差异具有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后LVEDD及LVESD均降低,而LVEF均升高,差异具有统计学意义(P<0.05);与对照组比较,研究组患者治疗后LVEDD及LVESD较低,而LVEF较高,差异具有统计学意义(P<0.05)。结论:依折麦布联合阿托伐他汀治疗冠心病的临床疗效显著,能够降低患者血脂水平,改善氧化应激反应及心功能,值得临床推广应用。
Objective: To investigate the effect of ezetimibe combined with atorvastatin on oxidative stress and serum lipids in patients with coronary heart disease and its clinical efficacy. Methods: A total of 144 CHD patients treated in our hospital from August 2013 to August 2016 were randomly divided into control group and study group, with 72 patients in each group. Patients in the control group were treated with atorvastatin and nitroglycerin, and patients in the study group were treated with atorvastatin and ezetimibe. The levels of serum peroxidase (MPO), malondialdehyde (MDA), superoxide dismutase (SOD), total cholesterol (TC), triglyceride (TG) and low density lipoprotein -C) and high-density lipoprotein (HDL-C) levels, cardiac function and clinical efficacy. Results: The total clinical effective rate (87.5%) in the study group was significantly higher than that in the control group (76.4%), the difference was statistically significant (P <0.05); after treatment, serum MDA and MPO levels decreased (P <0.05). Compared with the control group, serum MDA and MPO levels in the study group were lower and SOD levels were higher, the difference was statistically significant (P <0.05) ). After treatment, the levels of HDL-C in both groups increased, while the levels of LDL-C, TC and TG decreased, with statistical significance (P <0.05). Compared with the control group, serum HDL- The level of C was higher, while the levels of LDL-C, TC and TG were lower, the difference was statistically significant (P <0.05). Compared with those before treatment, LVEDD and LVESD both decreased and LVEF increased after treatment in both groups (P <0.05). LVEDD and LVESD in study group were lower than those in control group LVEF higher, the difference was statistically significant (P <0.05). Conclusion: Ezetimibe combined with atorvastatin in treatment of coronary heart disease significant clinical effect, can reduce blood lipid levels, improve oxidative stress and cardiac function, it is worthy of clinical promotion and application.